Phản Ứng Lipodystrophy Đối Với Insulin

Ahmed I, Goldstein B.: Diabetes mellitus. Clin Dermatol 2006; 24: 237–46 Richardson T, Kerr D.: Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 2003; 4: 661–7 Píerard-Franchimont C, Hermanns-Lê T, Scheen A.: Cutaneous complications of insulinotherapy: a drug-related problem on the decline. Rev Med Li`ege 2005; 60: 564–5 Lawrence RD.: Local insulin reactions. Lancet 1925; 1: 1125–6 Schernthaner G.: Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16 Suppl. 3: 155–65 Lapie`re ChM, Piérard GE, Hermanns JF.: Unusual extensive granulomatosis after long term use of plastic syringes for insulin injections. Dermatologica after long term use of plastic syringes for insulin injections. Dermatologica 1982; 165: 55–67 Paley RG, Tunbridge RE.: Dermal reactions to insulin therapy. Diabetes 1952; 1: 22–7 Arkins JA, Engoring NH, Lennon E.: The incidence of skin reactivity to insulin in diabetic patients. J Allergy 1962; 33: 69–72 Patterson R, Roberts M, Grammer LC:. Insulin allergy: re-evaluation after two decades. Ann Allergy 1990; 64: 459–62 Grammer LC.: Immunologic reaction to insulin and other proteins. Immunol Allergy Clin North Am 1998; 18: 809–16 Sola-Gazagnes A, Pecquet C.: Allergie á l’insuline en 2003. Paris: Journées de Diabétologie de l’Hôtel Dieu, Flammarion Médecine-Sciences, 2004: 161–79 Pickup J, Keen H.: Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593–8 Radermecker RP, Scheen AJ.: Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004; 20: 178–88 Ratner RE, Phillips TM, Steiner M.: Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes 1990; 39: 728–33 Oiknine R, Bernbaum M, Mooradian AD.: A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 2005; 65: 325–40 Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174–83 Brange J, Owens DR, Kang S.: Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923–54 Ottesen JL, Nilsson P, Jami J.: The potential immunogenicity of human insulin and insulin analogues evaluated in a transgene mouse model. Diabetologia 1994; 37: 1178–85 Radermecker RP, Scheen AJ.: Treatment of allergy to insulin using continuous subcutaneous insulin infusion with short-acting insulin analogues. Infusystems International 2004; 3: 1–5 Castera V, Dutour-Meyer A, Koeppel M.: Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion. Diabetes Metab 2005; 31: 391–400 Guinn TS, Bailey GJ, Mecklenburg RS.: Factors related to discontinuation of subcutaneous insulin infusion therapy. Diabetes Care 1988; 11: 46–51 Chantelau E, Lange G, Sonnenberg GE.: Acute cutaneous complications and catheter needle colonization during insulin-pump treatment. Diabetes Care 1987; 10: 478–82 Kahn CR, Rosenthal AS.: Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979; 2: 283–95 McNally PG, Jowett NI, Kurinczuk JJ.: Lipohypertrophy and lipoatrophy phenoxycomplicating treatment with highly purified bovine and porcine insulins. Post-grad Med J 1988; 64: 850–3 Flagothier C, Piérard GE, Quatresooz P.: Cutaneous myospherulosis and membranous lipodystrophy: extensive presentation in a patient with severe steroid-induced dermal atrophy. J Eur Acad Dermatol Venereol 2006; 20: 457–60 Flagothier C, Quatresooz P, Piérard GE.: Electromagnetic lipolysis and semicircular lipoatrophy of the thighs. Ann Dermatol Venereol 2006; 133: 577–80 Hauner H, Stockamp B, Haaster B.: Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996; 104: 106–10 Fujikura J, Fujimoto M, Yasue S.: Insulin-induced lipohypertrophy: report of a case with histopathology. Endocr J 2005; 52: 623–8 Quatresooz P, Xhauflaire-Uhoda E, Piérard-Franchimont C.: Cellulite histopathology and related mechanobiology. Int J Cosmet Sci 2006; 28: 207–10 Raile K, Noelle V, Landgraf R.: Insulin antibodies are associated with type 1 diabetes. Exp Clin Endocrinol Diabetes 2001; 109: 393–6 Young RJ, Hannan WJ, Frier BM.: Diabetic lipohypertrophy delays insulin absorption. Diabetes Care 1984; 7: 479–80 Chowdhury TA, Escudier V.: Poor glycemic control caused by insulin induced lipohypertrophy. BMJ 2003; 327: 83–4 Hardy KJ, Gill GV, Bryson JR.: Severe insulin-induced lipohypertrophy successfully treated by liposuction. Diabetes Care 1993; 16: 929–30 Samdal F, Amland PF, Sandsmark M.: Diabetic lipohypertrophy treated with suction-assisted lipectomy. J Intern Med 1993; 234: 489–92 Radermecker RP, Scheen AJ.: Allergy reactions to insulin: effects of continuous insulin infusion and insulin analogues.Diabetes Metab Res Rev. In press Kim KT, Ahn SK, Choi EH.: Membranous lipodystrophy associated with insulin lipoatrophy. Int J Dermatol 1997; 36: 299–301 Murao S, Hirata K, Ishida T.: Lipoatrophy induced by recombinant human insulin injection. Intern Med 1998; 37: 1031–3 Mu L, Goldman JM.: Human recombinant DNA insulin-induced lipoatrophy in patient with type 2 diabetes mellitus. Endocr Pract 2000; 6: 151–2 Felner EI.: Human insulin-induced lipoatrophy. J Pediatr 2003; 142: 448 Atlan-Gepner C, Bongrand P, Farnarier C.: Insulin-induced lipoatrophy in type 1 diabetes: sta possible tumor necrosis factor-a-mediated dedifferentiation of adipocytes. Diabetes Care 1996; 19: 1283–5 Jermendy G, Nadas J, Sapi Z.: “Lipoblastoma-like” lipoatrophy induced by human insulin: morphological evidence for dedifferentiation of adipocytes? Diabetologia 2000; 43: 955–6 Reeves WG, Allen BR, Tattersall RB.: Insulin-induced lipoatrophy: evidence for an immune pathogenesis. BMJ 1980; 1: 1500–6 Beltrand J, Guilmin-Crepon S, Castanet M.: Insulin allergy and extensive lipoatrophy in child with type 1 diabetes. Horm Res 2006; 65: 253–60 Whitley TH, Lawrence PA, Smith CL.: Amelioration of insulin lipoatrophy by dexamethasone injection. JAMA 1976; 235: 839–40 Ramos AS, Farias MA.: Human insulin-induced lipoatrophy: a successful treatment with glucocorticoid. Diabetes Care 2006; 29: 926–7 Logwin S, Conget I, Jansa M.: Human insulin-induced lipoatrophy: successful treatment using a jet-injection device errpublished erratum appears in Diabetes Care. Diabetes Care 1996; 19: 255–6 Meyer L, Hadjadj S, Guerci B.: Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion. Diabetes Metab 1998; 24: 544–6 Lougheed W, Albisser AM, Martindale HM.: Physical stability of insulin formulations. Diabetes 1983; 32: 424–32 Chantelau E, Lange G, Gasthaus M.: Interaction between plastic catheter tubings and regular insulin preparations used for continuous subcutaneous insulin-infusion therapy. Diabetes Care 1987; 10: 348–51 Melberg SG, Havelund S, Villumsen J.: Insulin compatibility with polymer materials used in external pump infusion systems. Diabet Med 1988; 5: 243–7 Van den Hove J, Jacobs M-C, Tennstedt D.: Allergic contact dermatitis from acrylates in insulin pump infusion sets. Contact Dermatitis 1996; 35: 108 Jolanki R, Kanerva L, Estlander T.: Allergic contact dermatitis from phenoxyethoxy ethylacrylates in optical fiber coating, and glue in an insulin pump set. Contact Dermatitis 2001; 45: 36–7 Saccabusi S, Boatto G, Asproni B.: Sensitization to methyl methacrylate in the plastic catheter of an insulin pump infusion set. Contact Dermatitis 2001; 45: 47–8 Boom BW, Van Driel LM.: Allergic contact dermatitis to epoxy resin infusion sets of an insulin pump.Contact Dermatitis1985; 12:280 Busschots AM, Meuleman V, Poesen N.: Contact allergy to components of glue in insulin pump infusion sets. Contact Dermatitis 1995; 33: 205–6 Corazza M, Maranini C, Aleotti A.: Nickel contact dermatitis due to needle of an insulin pump, confirmed by microanalysis. Contact Dermatitis 1998; 39: 144 Meier A, Weerakoon J, Dandona P.: Bilateral abdominal lipohypertrophy after continuous subcutaneous infusion of insulin. BMJ 1982; 283: 1539 Chantelau E, Reuter M, Schotes S.: Severe lipoatrophy with human insulin: successfully treated by CSII. Diabet Med 1993; 10: 580–1 Griffin ME, Feder A, Tamborlane WV.: Lipoatrophy associated with lispro in insulin pump therapy. Diabetes Care 2001; 24: 174 Ampudia-Blasco FJ, Hasbum B, Carmena R.: A new case of lipoatrophy with lispro insulin in insulin pump therapy. Diabetes Care 2003; 26: 953–4 Arranz A, Andia V, Lopez-Guzman A.: A case of lipoatrophy with lispro insulin without insulin pump therapy. Diabetes Care 2004; 27: 625–6 Ampudia-Blasco FJ, Girbes J, Carmena R.: A case of lipoatrophy with insulin glargine. Diabetes Care 2005; 28: 2983 Fineberg SE, Huang J, Brunelle R.: Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care 2003; 26: 89–96 Roper NA, Bilous RW.: Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro. Diabet Med 1998; 15: 1063–4 Johansson U-B, Amsberg S, Hannerz L.: Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care 2005; 28: 2025–7 Lougheed WD, Zinman B, Strack TR.: Stability of insulin lispro in insulin infusion systems. Diabetes Care 1997; 20: 1061–5 Defelippis MR, Bell MA, Heyob JA.: In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther 2006; 8: 358–68 Burge MR, Carey JD.: Vitiligo associated with subcutaneous insulin lispro infusion in type 1 diabetes. Diabetes Care 2004; 27: 275–6 Kemp EH, Waterman EA, Weetman AP.: Autoimmune aspects of vitiligo. Autoimmunity 2001; 34: 65–77